Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

Similar articles for PubMed (Select 15502839)

1.

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV.

Nat Med. 2004 Nov;10(11):1240-4. Epub 2004 Oct 24. Erratum in: Nat Med. 2004 Dec;10(12):1397.

PMID:
15502839
3.

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.

Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, Lang T, Veldsman A, Hatherill M, Merwe Lv, Fletcher HA, Mahomed H, Hill AV, Hanekom WA, Hussey GD, McShane H.

J Infect Dis. 2008 Aug 15;198(4):544-52. doi: 10.1086/590185. Erratum in: J Infect Dis. 2011 Jul;204(1):176.

4.

Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.

Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL.

Clin Vaccine Immunol. 2010 May;17(5):793-801. doi: 10.1128/CVI.00006-10. Epub 2010 Mar 31.

5.

Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis.

You Q, Jiang C, Wu Y, Yu X, Chen Y, Zhang X, Wei W, Wang Y, Tang Z, Jiang D, Wu Y, Wang C, Meng X, Zhao X, Kong W.

Scand J Immunol. 2012 Jan;75(1):77-84. doi: 10.1111/j.1365-3083.2011.02629.x.

PMID:
21916923
6.

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.

McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):47-52. Epub 2005 Jan 21. Review.

PMID:
15687027
8.
9.

Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.

Tang C, Yamada H, Shibata K, Maeda N, Yoshida S, Wajjwalku W, Ohara N, Yamada T, Kinoshita T, Yoshikai Y.

J Infect Dis. 2008 May 1;197(9):1263-74. doi: 10.1086/586902.

10.

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.

Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, Keyser A, Moyo S, Brittain N, Lawrie A, Gelderbloem S, Veldsman A, Hatherill M, Hawkridge A, Hill AV, Hussey GD, Mahomed H, McShane H, Hanekom WA.

Eur J Immunol. 2010 Jan;40(1):279-90. doi: 10.1002/eji.200939754. Erratum in: Eur J Immunol. 2011 May;41(5):1501.

11.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
12.

Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.

Vordermeier HM, Rhodes SG, Dean G, Goonetilleke N, Huygen K, Hill AV, Hewinson RG, Gilbert SC.

Immunology. 2004 Jul;112(3):461-70.

13.

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.

Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE, Ambrozak DR, Precopio ML, Scheinberg P, Alder NC, Roederer M, Koup RA, Douek DC, Hill AV, McShane H.

Eur J Immunol. 2007 Nov;37(11):3089-100. Erratum in: Eur J Immunol. 2011 May;41(5):1501.

14.

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.

Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whelan KT, Alder NC, Sander CR, Hill AV, McShane H.

Vaccine. 2008 Sep 26;26(41):5269-75. doi: 10.1016/j.vaccine.2008.07.040. Epub 2008 Aug 3.

15.

MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.

Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, van der Werff NM, Kersbergen A, Ottenhoff TH, Heidt PJ, Gilbert SC, Gicquel B, Hill AV, Martin C, McShane H, Thomas AW.

PLoS One. 2009;4(4):e5264. doi: 10.1371/journal.pone.0005264. Epub 2009 Apr 15. Erratum in: PLoS One. 2011;6(2). doi:10.1371/annotation/e599dafd-8208-4655-a792-21cb125f7f66.

16.

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity.

Hoft DF, Blazevic A, Stanley J, Landry B, Sizemore D, Kpamegan E, Gearhart J, Scott A, Kik S, Pau MG, Goudsmit J, McClain JB, Sadoff J.

Vaccine. 2012 Mar 9;30(12):2098-108. doi: 10.1016/j.vaccine.2012.01.048. Epub 2012 Jan 30.

PMID:
22296955
17.

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.

Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, Thacker T, Gilbert SC, McShane H, Hill AV, Xing Z, Hewinson RG.

Infect Immun. 2009 Aug;77(8):3364-73. doi: 10.1128/IAI.00287-09. Epub 2009 Jun 1. Erratum in: Infect Immun. 2011 May;79(5):2134.

18.

Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus.

Feng CG, Blanchard TJ, Smith GL, Hill AV, Britton WJ.

Immunol Cell Biol. 2001 Dec;79(6):569-75.

19.

Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis.

Singh S, Saraav I, Sharma S.

Vaccine. 2014 Feb 3;32(6):712-6. doi: 10.1016/j.vaccine.2013.11.065. Epub 2013 Dec 2. Review.

PMID:
24300592
20.

Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A.

Harris SA, Satti I, Matsumiya M, Stockdale L, Chomka A, Tanner R, O'Shea MK, Manjaly Thomas ZR, Tameris M, Mahomed H, Scriba TJ, Hanekom WA, Fletcher HA, McShane H.

Clin Vaccine Immunol. 2014 Jul;21(7):1005-11. doi: 10.1128/CVI.00128-14. Epub 2014 May 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk